Thursday, 6 December 2018

BioLargo Spotlight: Odor-No-More® Participates in Isle Utilities’ US TAG Events

Last week, BioLargo participated in two events put on by Isle Utilities, Inc., a leading clean tech accelerator group that operates globally in the water, waste, and energy sectors. These events are part of Isle Utilities’ Technology Approval Group (TAG) program, an innovation forum where leading early-adopter end-users, including major municipalities and utility companies, are exposed to innovative technology providers. Only a handful of companies are invited to each event, having been selected through a vote by end-user members.

Isle Utilities consists of a team of scientists, engineers, and industry experts from around the world, and they operate their TAG program in Europe, the US, Australia, Singapore, Brazil, and South Africa. According to their website, Isle Utilities is “an independent technology and innovation consultancy that brings together technical and commercial specialists to facilitate relationships. [Their] team are highly skilled engineers and scientists with extensive and diverse consulting experience”. Their TAG program is well-respected for its ability to identify disruptive new technologies for the water and wastewater sector.

To learn more about the TAG program, watch Isle Utilities’ video:



Isle Utilities has a thorough vetting process to choose companies for utilities to vote on to participate in US TAG events, including a rigorous technical review. This ensures that participating municipalities and utilities are only exposed to the very best innovative technology developers and product suppliers. The fact that BioLargo was invited to participate in TAG events represents important industry recognition of its innovative product CupriDyne® Clean.

BioLargo participated in the San Antonio, TX and Dayton, OH, TAG US events, where decision-makers representing municipal water utilities learned about the company’s disruptive industrial odor and VOC control product, CupriDyne Clean.

Odor-No-More’s Vice President of Industrial Sales AJ Sexton V represented the company. He commented on the events, “The Isle Utilities TAG events were terrific. We presented to over 60 people from regional utilities between the two meetings and had the opportunity to have direct one-on-one discussions with representatives from numerous potential clients. We applaud Isle Utilities for organizing these great events.”

US TAG attendees. Odor-No-More's AJ Sexton is 7th from the left

Wednesday, 5 December 2018

BioLargo Corporate Deck as Presented at the 11th Annual LD Micro Main Event Investor Conference

Dear Stockholder

Please see the presentation 'deck' delivered at the LD Micro XI Main Event in Los Angeles, which can be viewed at the link shown below as well as the written answers to the most important questions just below the slides: 

What's New? and Why Now?  


BioLargo LD Micro Dec 2018 as presented 12042018

The event was great for BioLargo.  The two most common questions fielded were:

What's new?

Answer:

1.     sales are setting new records; +$1 million YTD in 2018
2.     two operating divisions are nearing profitability - Odor-No-More and BLEST Engineering
3.     Odor-No-More signed 4 industry leaders to national purchase agreements and now operating as a 'full solution service provider' for a $1.3 billion total addressable market for odor and VOC control capable of carrying the entire company as it matures
4.     100% area adoption in Orange County and Los Angeles with one client for CupriDyne Clean
5.     critical proof of claim for AOS clean water technology role in removing micro pollutants
6.     clarity for FDA pathway success for Clyra Medical
7.     nearing $1m funds raised to close purchase agreement for stem cell therapy technology (SkinDisc)
8.     preparing to uplist to Nasdaq - engaged NY investment banking firm to lead the process
9.     and more

And:

Why now?

With $23 million in investment capital over the last decade, we have advanced our platform of sustainable technologies and products to a point where they are technically proven and well-situated for market adoption. For each of our technologies we have a strategy to disrupt a number of very large markets with better solutions to some of the world's most pressing problems in the areas of clean air, clean water and advanced wound care.  

We are now situated to put capital to work to grow revenues and ultimately make profits.  We remain convinced that BioLargo will become a great “American Success Story” while paying homage to our Canadian inventors and benefactors as well as our army of loyal investors.  

Capital and patience are key! 

Thank you and call me. 

Dennis Calvert
President & CEO
BioLargo, Inc.

Wednesday, 28 November 2018

BioLargo Spotlight: BioLargo Engineering Talks About Natural Gas Conversion


You might remember in a couple of different blog posts over the past few months, we discussed two ongoing projects for clients building plants that will generate fuels – from solid waste and from natural gas. The environmental engineering work we do for these clients is – we believe – exceptionally important both to the growth prospects of our company and to our overarching company goal of helping foster a sustainable future for the world. We also believe that as part of our role as environmental stewards, it’s important to promote education in the areas of science, technology, and environmental engineering. For that reason, today we want to discuss one of the areas relevant to this work– the process of conversion of natural gas into usable fuels.

A bit of Chemistry

In theory it is possible to convert any run-of-the-mill hydrocarbon, such as methane, which makes up about 85% of natural gas, into almost any other hydrocarbon.  In fact, nature does this sort of thing all the time.  Plants, comprised of many complex hydrocarbons, are converted through time, heat and pressure into crude oil, coal and natural gas.  Plants themselves are chemical factories in miniature.  Through photosynthesis, plants convert sunlight and carbon dioxide into complex sugars, cellulose and myriad other complex hydrocarbons with myriad physical and chemical properties.  By adding in some nitrogen, oxygen and few other ingredients from the soil, plants can make proteins, oils, sugars, and in some cases, such as the nightshade plant, alkaloid poisons.  Plants create chemicals that mankind refines into medicines and drugs.  For example, morphine, nicotine, aspirin and caffeine are four plant supplied chemicals that directly impact man’s wellbeing, for better or worse.  The conversion of natural gas into liquid fuels in our client projects is not nearly as complex as what is going on in that oak tree growing in your back yard.

In brief, the process goes something like this:  methane from natural gas is partially oxidized, that is partially burned in a low oxygen environment to form carbon monoxide (CO) and hydrogen (H2).  Water vapor is added as a source of additional hydrogen.  Some of the CO reacts with the water vapor (the “water gas shift reaction”) to form hydrogen (H2) and carbon dioxide (CO2).  The CO2 formed in the reaction is then stripped from the gas mixture.  In some designs, direct steam reforming is used where water vapor is directly reacted at high temperature, with methane to form CO and H2.  The CO and H2 are then pushed through a catalyst, which converts the two simple chemicals into larger molecules, typically alkanes, which are saturated hydrocarbons like methane or propane.  The catalyst selected controls whether synthetic gasoline, diesel, jet fuel or paraffin waxes is produced.

A bit of History

Perhaps because we don’t see natural gas conversion plants on every street corner, we tend to think of the technology as something new, at bit cutting edge.  But the truth is that the process was developed in 1925 by two German chemists, Franz Fischer and Hans Tropsch.  Today we call the process the Fischer-Tropsch process or “F-T” for short, I imagine to avoid having to learn how to pronounce Tropsch (usually pronounced Trope, with a long “o”).  Germany made great use of the process in World War II - having relatively small native oil reserves, Germany was able to fuel their war machine using the Fischer-Tropsch process by converting coal into liquid fuels.  The WWII German synthetic fuels industry was able to produce 3.7 million barrels per month by early 1944, utilizing 25 F-T plants scattered across Germany and the occupied lands.  The Pölitz plant alone was able to produce 575,000 tons of fuel in 1943.  A documentary on the topic can be viewed at https://www.youtube.com/watch?v=jwHypKFYzGg.

A bit of Technology

The F-T process uses a specialized catalyst to facilitate the conversion of CO into heavier molecules, mostly alkanes.  An alkane is a class or family of chemicals that all share the general formula CnH2n+2. Don’t let the symbols throw you.  The formula just says that for every (n) number of carbon atoms there are (2n+2) hydrogen atoms, for example C3H8 or C6H14. The family includes many useful compounds whose names are in general use by the public, such as methane, butane, propane, and octane, to name a few.  As the number of carbon atoms in each molecule increases, the higher the compound’s boiling point becomes.  Methane with one carbon is a gas, even at the North Pole in January.  Propane with three carbons is a gas at room temperature but can be compressed to form a liquid for use in gas grills, and home heating as well as other uses.  Octane, with eight carbons, is a liquid with about the same boiling point as gasoline.  Paraffin wax is an alkane with 20 to 30 carbon atoms and is a solid at room temperature but is still flammable if given enough encouragement.  The F-T process produces a mixture of alkanes from methane (one carbon) to paraffin wax (30 or more carbon atoms).

The percentage of each alkane produced is controlled by the selection of catalyst and the operating conditions in the F-T catalytic converter.  The most commonly used catalysts include those made from transition metals like cobalt, iron and ruthenium. For natural gas F-T processes, cobalt is the most commonly used.  Unfortunately, it is impossible to have the process produce only the alkane desired.  Mixtures of different alkanes are inevitable. So, the F-T unit is often followed by a catalytic cracker where the heavier alkanes can be thermally “cracked” to reform lighter, often more desirable liquid fuels.  The process produces very pure liquid fuels, such as ultra-low sulfur synthetic diesel and high purity jet fuel.

Technology has surged forward since WWII and modern materials science has created new catalysts that are significantly more efficient at converting CO into alkanes and allowing simpler upstream gasification steps.  The newer catalysts also help narrow the range of alkanes produced, making refining the final products easier and more cost effective.  It is now possible to produce ultra-low sulfur diesel at prices less than the current retail price of petroleum sourced ultra-low sulfur diesel. Modern designs also include secondary processes to capture and make use of what were once waste materials, such as carbon dioxide, extra hydrogen and organic chemicals that were formed as byproducts.

A bit of Economics

So, if the technology is mature and the raw materials to feed the process are plentiful, why don’t we see F-T conversion plants on every street corner?  The simplest answer is we don’t need to.  The graph below, taken from the US Government website https://www.energy.gov shows that the United States started to produce more oil than it imported in early 2014, and it’s simply more cost-efficient for us to procure oil the old-fashioned way.

















It remains much less expensive to drill, pump and refine crude oil than to create synthetic fuels from other hydrocarbons. As long as the price of crude oil is below some undefined trigger point, synthetic fuel plants will be rare. Note that we mentioned that we could produce F-T ultra-low sulfur diesel fuel at less than the retail price of petroleum based ultra-low sulfur diesel.  However, to be competitive, the production price needs to be competitive with the wholesale, raw production price of the petroleum-based products.

Occasionally, the undefined trigger point is reached and excitement builds in the synthetic fuels industry.  Each time world events create political unrest and the price of crude oil goes up, the number of proposed or planned synthetic fuel plants escalates.  However, by the time the planning, design, and permitting of a new plant is completed, the crisis is over, and the price of oil falls back making the new plants economically unsound.


There are other reasons we don’t have F-T conversion plants across the country.  One, the capital and infrastructure invested in traditional petroleum refining is staggering and not easily abandoned.  The mega-companies that make up the oil industry are resistant to new perhaps, dare I say it, disruptive approaches.  And, small companies don’t have the economies of scale to easily compete in that market.  Another reason is the history of the F-T process itself, being used so effectively by the Nazis in WWII.  It was not, of course, the fault of the process that its first great accomplishment was to fuel what is generally considered the most evil regime in the history of the planet.  Nevertheless, the stain of the Nazis remains and is perpetuated unintentionally by every professor who has ever taught about the F-T process, who dwell on the history and first large-scale use of the technology.

Of course, there will come a day when the world’s oil reserves will be expended, and other sources of energy will need to be developed and exploited.  Perhaps there is some comfort in the knowledge that as that day approaches, there already exists a technology that can convert less useful hydrocarbons into more useful forms; trash into treasure in a sense.  BLEST is already involved with a project to convert municipal solid waste into F-T fuels with the expectation that 1,000 tons of high-grade synthetic fuels will be produced daily, consuming materials that would otherwise go to the local landfill.  Trash into treasure, indeed.


In theory, if all our fuel came from F-T conversion plants, we would have overall better environmental outcomes from our fuel production because of the absence of drilling, fracking, and refining of crude oil and the environmental outcomes associated with them. BLEST is therefore proud to be a part of these projects and hopes to assist industry leaders in fostering this type of process and technology throughout the future.



By Randall Moore

President, BioLargo Engineering, Science & Technologies (BLEST)

Mr. Moore is an engineer/executive with more than 30 years of industrial commercial experience. Most recently he served as Manager of Operations for Consulting and Engineering for the Knoxville, Tennessee office of CB&I Environmental & Infrastructure, Inc. Prior to that, from February 2013 – May 2017, he was the Manager of Operations at Integrated Environmental Solutions a Consulting and Engineering group within CB&I, Environmental and Infrastructure, Inc.



Friday, 23 November 2018

A Thanksgiving Message from BioLargo and an Important Press Release on Micropollutant Treatment by the AOS


Dear Stockholder,

First, let me wish you all a Happy Thanksgiving and say THANK YOU! 













We have so much to be thankful for, and a few highlights deserve a mention in light of this special holiday:
  • The BioLargo Technology. When we first met Ken Code over a decade ago, he shared the gift of his scientific discoveries and the enormous and important duty that comes with unique and innovative technologies like ours designed to make the world a better place. 
  • You, and each of our investors. Without our investors’ continued support, our journey and our technologies would be impossible. Our journey – from idea to fully developed and finished products, and all the barriers that come with it, is most certainly not for the faint of heart. We have had to fight for every inch and the journey has most certainly tested our resolve and patience. Rest assured, we are not deterred, and because of our continual progress, we are more excited than ever before. And we thank you for your support on this journey.
  • Team members. We have assembled a diverse team of highly qualified innovators, engineers, scientists, and operators that are fearless and driven by our mission. They are special and critical to our ongoing success.
  • Grant Supporters. We have now received more than 60 grants from a host of Canadian federal and provincial agencies as well as industry members in support of our clean water technology. The pursuit of such an ambitious vision like ours that can impact the world for good would never be possible without support like this.  It is and will continue to be critical to our ongoing success.
  • Critics. Yes, we are grateful for the insights of our critics. “Iron sharpens iron” – and our tools have been finely honed to razor sharpness. Remember, in each of our pursuits – clean air, clean water and advanced wound care – we are an innovator presenting novel scientific discoveries that have never been seen before in such meaningful pursuits. Because our technologies are novel and unprecedented, our challenge has been to prove, prove and prove again. 

As an example, we have just released a press release detailing a very important recent study where the AOS was shown, by an expert 3rd party research lab at the University of Alberta, to effectively eliminate specific micropollutant pharmaceuticals that are a major problem in municipal wastewater treatment. Because there is no economically feasible solution for these contaminants in municipal wastewater treatment, these results make the AOS a breakthrough in advanced municipal wastewater treatment. The press release is below.

Our continued success in science and now our growing commercial success reminds us to be THANKFUL and excited for 2019.

Happy Thanksgiving,

Dennis Calvert
President and CEO
BioLargo, Inc.


Press Release below



BioLargo's Advanced Oxidation System (AOS) Test Data Show Breakthrough to Treat and Reduce the Toxicity of Micropollutants Associated with Municipal Wastewater

Westminster, CA - November 20, 2018 - BioLargo, Inc. (OTCQB:BLGO), developer of sustainable science and technologies and a full-service environmental engineering company, today announced the completion of a third-party study indicating the company's Advanced Oxidation System (AOS) water treatment technology can eliminate certain toxic micropollutant contaminants associated with municipal wastewater. Micropollutants are widespread and persistent contaminants of significant concern to regulators due to environmental and human health concerns, and are difficult to treat using conventional wastewater treatment technologies (such as UV and biological treatment). Consequently, discharge of micropollutants in municipal wastewater effluents is currently a high priority issue for regulators and municipalities. Due to the lack of existing economically viable solutions for the elimination of micropollutants from municipal wastewater, these findings make the AOS a breakthrough in advanced municipal wastewater treatment.

BioLargo had previously reported on a third-party study conducted in collaboration with researchers at the Centre Des Technologies de L'Eau suggesting its AOS technology effectively removes certain pharmaceutical by-products (i.e., micropollutants) from water (Link here).
In this follow-up study conducted by Dr. Greg Goss, an expert in aquatic toxicology at the University of Alberta, in collaboration with BioLargo's Canadian subsidiary BioLargo Water, Inc., Dr. Goss examined the environmental safety of AOS-treated municipal wastewater to demonstrate it did not produce toxic by-products, and whether the AOS' ability to eliminate pharmaceuticals from water would improve the environmental safety and water quality of municipal wastewater "spiked" with high concentrations of micropollutant contaminants of particular concern to regulators.

This study succeeded on both fronts, demonstrating that water treated by the AOS technology was non-toxic to certain aquatic organisms typically used for testing whole effluent toxicity for the EPA's National Pollutant Discharge Elimination System (NPDES) Permits Program, such as
Daphnia and rainbow trout, as well as zebrafish embryos. Additionally, the AOS eliminated biomarker responses of municipal wastewater that has been experimentally contaminated (spiked) with compounds (benzo[a]pyrene and 17β-estradiol) known to negatively affect those organisms.

Further, the study showed that the AOS reduces the well-documented aberrant endocrine disrupting chemical (EDC) effects of 17β-estradiol (an estrogen derivative) on rainbow trout. AOS was able to reduce both the normal EDC effects of municipal wastewater on rainbow trout and was also successful in removing 17β-estradiol from municipal wastewater spiked with much higher levels of the hormone.

These results represent promising evidence that the AOS can remove micropollutants that are an emerging concern to the water treatment industry. Given that micropollutants are bioactive and persistent contaminants that are not removed by traditional wastewater treatment methods, AOS has the potential to fill an important niche treatment gap with growing demand: effective and cost-efficient removal of micropollutants in wastewater treatment.

Dr. Greg Goss commented on the results, "More work is needed, but it appears that the AOS treatment is a major technical breakthrough for the removal of micropollutants from wastewater."

This work was funded in part by the Canadian Natural Science and Engineering Research Council (NSERC) and the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).

Wednesday, 21 November 2018

BioLargo’s Advanced Oxidation System (AOS) Test Data Show Breakthrough to Treat and Reduce the Toxicity of Micropollutants Associated with Municipal Wastewater


Westminster, CA – November 20, 2018 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable science and technologies and a full-service environmental engineering company, today announced  the completion of a third-party study indicating the company’s Advanced Oxidation System (AOS) water treatment technology can eliminate certain toxic micropollutant contaminants associated with municipal wastewater. Micropollutants are widespread and persistent contaminants of significant concern to regulators due to environmental and human health concerns, and are difficult to treat using conventional wastewater treatment technologies (such as UV and biological treatment). 
Consequently, discharge of micropollutants in municipal wastewater effluents is currently a high priority issue for regulators and municipalities. Due to the lack of existing economically viable solutions for the elimination of micropollutants from municipal wastewater, these findings make the AOS a breakthrough in advanced municipal wastewater treatment.

BioLargo had previously reported on a third-party study conducted in collaboration with researchers at the Centre Des Technologies de L’Eau suggesting its AOS technology effectively removes certain pharmaceutical by-products (i.e., micropollutants) from water (Link here).

In this follow-up study conducted by Dr. Greg Goss, an expert in aquatic toxicology at the University of Alberta, in collaboration with BioLargo’s Canadian subsidiary BioLargo Water, Inc., Dr. Goss examined the environmental safety of AOS-treated municipal wastewater to demonstrate it did not produce toxic by-products, and whether the AOS’ ability to eliminate pharmaceuticals from water would improve the environmental safety and water quality of municipal wastewater “spiked” with high concentrations of micropollutant contaminants of particular concern to regulators.

This study succeeded on both fronts, demonstrating that water treated by the AOS technology was non-toxic to certain aquatic organisms typically used for testing whole effluent toxicity for the EPA’s National Pollutant Discharge Elimination System (NPDES) Permits Program, such as Daphnia and rainbow trout, as well as zebrafish embryos. Additionally, the AOS eliminated biomarker responses of municipal wastewater that has been experimentally contaminated (spiked) with compounds (benzo[a]pyrene and 17β-estradiol) known to negatively affect those organisms.

Further, the study showed that the AOS reduces the well-documented aberrant endocrine disrupting chemical (EDC) effects of 17β-estradiol (an estrogen derivative) on rainbow trout. AOS was able to reduce both the normal EDC effects of municipal wastewater on rainbow trout and was also successful in removing 17β-estradiol from municipal wastewater spiked with much higher levels of the hormone.

These results represent promising evidence that the AOS can remove micropollutants that are an emerging concern to the water treatment industry. Given that micropollutants are bioactive and persistent contaminants that are not removed by traditional wastewater treatment methods, AOS has the potential to fill an important niche treatment gap with growing demand: effective and cost-efficient removal of micropollutants in wastewater treatment.

Dr. Greg Goss commented on the results, “More work is needed, but it appears that the AOS treatment is a major technical breakthrough for the removal of micropollutants from wastewater.”
This work was funded in part by the Canadian Natural Science and Engineering Research Council (NSERC) and the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).

About BioLargo, Inc.

BioLargo, Inc. is an innovative technology developer and environmental engineering company driven by a mission to "make life better" by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air, and advanced wound care. We develop and commercialize disruptive technologies by providing the capital, support, and expertise to expedite them from "cradle" to "maturity" (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. Our subsidiary Clyra Medical (www.clyramedical.com) features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

Contact Information

Dennis Calvert President and CEO BioLargo, Inc. 949-643-9540 x2

Safe Harbor Act

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Tuesday, 20 November 2018

Edison Investment Research Posts Update on BioLargo

Edison Investment Research Group published an update on BioLargo, Inc. today internationally through their distribution channels.

You can read the full report at their website HERE, and you can also access their original analyst report on BioLargo HERE.






....................................................................

BioLargo made progress on multiple fronts during Q3 and subsequently toward becoming a fully fledged, diversified technology company. First, it announced that Clyra had received feedback from the FDA regarding the data necessary to complete the 510(k) application process, which should be finished in the next six months. Second, the company broke revenue records in October with BioLargo Engineering, Science & Technologies (BLEST) having its first break-even month. Finally, progress continues toward the 2019 launch of the AOS with the independent validation of the system’s capacity to eliminate micropollutants.
Already over the $1m sales hurdle for 2018
The company announced shortly after its earnings release in November 2018 that it had surpassed $1m in revenue for the year to date, in line with previous guidance. Revenue reported for Q3 was slightly down sequentially ($277,026 from $326,738), although this likely represents some lumpiness, as October subsequently broke records: the highest single month revenue for Odor-No-More revenue ($133,000), and BLEST ($89,000). Additionally, the company noted that BLEST revenue exceeded costs for the first time. The company noted that it plans to hire additional salespeople to support continued growth in 2019.
510(k) process moving forward for Clyra
The company provided an update on the regulatory process for its wound care product developed by Clyra. It previously initiated a 510(k) application with the FDA in June, which should allow for an expedited path to market. The most recent update confirmed that the FDA has asked for feedback on labelling and systemic toxicity to advance the process. The latter will require an animal study, which the company will engage a third party to perform. It believes that the process should be completed in the following six months.
AOS evaluated for elimination of micropollutants
In preparation for the planned 2019 launch, the Advanced Oxidation System (AOS) was evaluated by a third party for its capacity to eliminate a series of micropollutants from a water stream. Micropollutants are chemicals that might be present in small quantities but have an outsized impact on the environment. These include biologically active molecules such as drugs or potent toxins. These molecules can pose problems for traditional water purification systems. The study was successful and will culminate in the publication of a scientific paper on the system, at which time we expect to report additional details.
Source: Edison Investment Research

Monday, 19 November 2018

Press Release: BioLargo Tops $1M in Annual Revenues for First Time


Westminster, CA – November 19, 2018 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable science and technologies and a full-service environmental engineering company, today announced that it had passed an important milestone - $1,000,000 in annual revenues (year-to-date in 2018).

BioLargo president Dennis P. Calvert commented, “Sales of our odor control products have doubled each of the last four years. A recent order took us over the $1 million in sales mark for the year. Congratulations to Joe Provenzano and his team.”

Odor-No-More, Inc. President Joseph Provenzano commented on the milestone, “We are repeatedly told by our customers we have the best odor-control product in the market. We are leveraging that momentum by becoming a one-stop solution for industrial odor problems. We are focused on hiring additional sales people and plan to continue expanding our revenues in 2019.”

The company also reported in its recently filed 10-Q that its engineering subsidiary’s (BLEST) monthly revenues exceeded expenses for the first time in October. It’s important to note that while BLEST is growing its external services revenues, BioLargo also leans heavily on this division for development of its AOS water treatment system, support for the odor division, and implementation of AOS pilot projects.

BioLargo President and CEO Dennis Calvert said of the news, “Our success this year is an example of how great technology-based products and services can turn into disruptive commercial initiatives. We have only scratched the surface for both Odor-No-More and BLEST as they are heading toward profitability as stand-alone business units. Odor-No-More has evolved to become a total solutions provider for its customers, leveraging its considerable competitive advantages that make it a standout winner with a total addressable market that exceeds $1.3 billion in the USA alone (FN1). We are also excited about BioLargo Water and Clyra Medical Technologies, both of which are preparing to go commercial with their disruptive and sustainable products in 2019. While the costs of maintaining a public company also add to the overall company break even mark, we believe that continued growth in revenues for our two already commercial business units, Odor-No-More and BLEST, alone will achieve a level of performance capable of funding our company’s entire operating budget and more. They each broke monthly performance records in October, with Odor-No-More generating gross revenues of $133,000, and BLEST $89,000, for a combined total gross revenue of $222,000 (unaudited). While it may be too early to say we are at the inflection point of hockey stick growth, which we all know requires dedicated capital, we are preparing for another record-breaking year ahead.”

About BioLargo, Inc.

BioLargo, Inc. is an innovative technology developer and environmental engineering company driven by a mission to "make life better" by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air, and advanced wound care. We develop and commercialize disruptive technologies by providing the capital, support, and expertise to expedite them from "cradle" to "maturity" (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. Our subsidiary Clyra Medical (www.clyramedical.com) features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.
FN1 – Total addressable market assumes 100% market penetration at the landfills, transfer stations, and wastewater treatment plants located in the United States, and is based on average per-location revenue assumptions management believes to be reasonable.

Contact Information

Dennis Calvert President and CEO BioLargo, Inc. 949-643-9540 x2

Safe Harbor Act

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.


Thursday, 15 November 2018

BioLargo Reports Record Results


Westminster, CA – November 15, 2018 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable science and technologies and a full-service environmental engineering company, today announced the filing of its 10-Q quarterly report:
  • Sales increased 147% for the nine months ended September 30, 2018, compared with the nine months ended September 30, 2017
  • Monthly revenues exceeded expenses in the engineering division (BLEST) for the first time (in October)
  • Two pre-commercial field pilot projects are underway for the company’s AOS clean water technology and two more are in final stages of preparation. These pilots represent a landmark in AOS development, as they will pave the way for future commercial trials and market launch
  • Clyra Medical Technologies management met with the FDA in Washington DC to determine a clear pathway for clearance on its product submission under Section 510(k)
  • Details on a series of completed bridge financing arrangements
  • A Form S-1 that was filed with the SEC to pursue a public offering to raise capital to meet Nasdaq listing requirements that will be led by H.C. Wainwright & Co., LLC
The 10-Q quarterly report can be accessed here: LINK.

BioLargo President and CEO Dennis Calvert commented, “The future is bright for BioLargo. Our disruptive odor and VOC control product CupriDyne Clean represents our first significant commercial success that is unfolding, and we believe our two other innovative technology platforms – Clyra and the AOS – will follow in similar fashion soon. Our success with CupriDyne Clean is an example of our business model succeeding. We leverage innovative high-tech products that are meaningful in purpose and serve as cornerstones of a commercial strategy. We combine them with services, value, talent and partnerships to create a disruptive platform that wins market share. Our engineering group, BLEST has been instrumental in our efforts to scale-up and prepare for commercial readiness for our AOS clean water technology while at the same time it has been building its outside services clients that now include regional utilities, healthcare and Fortune 500 companies. We are thankful for the continued support of our stockholders and believe 2019 will be a great year.”


About BioLargo, Inc.

BioLargo, Inc. is an innovative technology developer and environmental engineering company driven by a mission to "make life better" by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air, and advanced wound care. We develop and commercialize disruptive technologies by providing the capital, support, and expertise to expedite them from "cradle" to "maturity" (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. Our subsidiary Clyra Medical (www.clyramedical.com) features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

Contact Information

Dennis Calvert President and CEO BioLargo, Inc. 949-643-9540 x2

Safe Harbor Act

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Monday, 5 November 2018

BioLargo® Spotlight: Odor-No-More heading to China for InnoStars Semi-Finals


In May of this year, we announced in a blog post that our odor and VOC control subsidiary Odor-No-More, Inc. had advanced to the semi-finals in the “Environmental Technology” track of the “China InnoStars Preliminary Competition.” One of 963 initial applicants, Odor-No-More is traveling this week to China for the competition along with six other companies in the Environmental Technology track.















The InnoSTARS Competition is a platform for innovative U.S. companies to compete and connect with investors and partners from China. It is the one and only innovation competition officially supported by both the U.S. and Chinese governments. In 2017, The InnoSTARS Competition was featured in the scientific and technology cooperative area at the first U.S.-China Social and Cultural Dialogue (SCD), co-chaired by U.S. Secretary of State Rex Tillerson and Chinese Vice Premier Liu Yandong. The goal of the competition is to provide US-based innovative technology companies with resources to enter the Chinese market. This competition, hosted by the US China Innovation Alliance (UCIA) and China Science and Technology Exchange Center (CSTEC), is supported by the Ministry of Science and Technology of the People’s Republic of China (MOST). It provides U.S.-based innovators and companies with a better understanding of the opportunities available to them in doing business with China and Chinese partners and investors. Join InnoSTARS to gain unique access to leading resources in China.






The Semi-Final events in China represent an opportunity for Odor-No-More to gain exposure in China’s tremendous and growing community of environmentally-minded investors, as well as to create inroads for sales of the company’s disruptive odor and VOC control product, CupriDyne Clean®. China has well-documented challenges in environmental areas such as air quality control and management of polluted, odorous rivers, creating a massive need for innovative solutions in the cleantech industry.

















While making inroads with CupriDyne Clean in the solid waste management industry in the US, we have begun targeting new vertical segments, including wastewater treatment. The InnoStars program is a stepping stone to expanding into new regional markets such as China. We believe the time is right to capitalize on CupriDyne Clean’s momentum and expand its adoption to new segments and markets with a need for effective, safe, environmentally friendly odor and VOC control.



What is a BioLargo Spotlight?

It’s an exciting time at BioLargo. We’re moving fast, and it can be difficult to keep our stockholders and the investing public informed of our progress. In light of this, we will be posting a series of short articles titled “BioLargo Spotlight”, highlighting certain business activities and other important information in between our required SEC filings. Of course, these do not replace our public filings, which contain more complete information than can be delivered in this forum, and thus we urge you to carefully read and rely on those filings for definitive information, and to review our risk factors and caution regarding forward-looking statements. We are optimistic about our business as we work hard to continue to grow and ultimately generate profits for our stockholders.  

Legal Disclaimer


Our attorneys remind us that while we believe these developments are important and that these small victories could add up and lead to big victories, at this stage they do not rise to the level of an official material disclosure. As the size and magnitude of these developments become material, we will naturally report that information in an 8-K and our regular SEC filings.

BioLargo, Inc.’s CEO Discusses Business Milestones and FDA Progress with Uptick Newswire’s Stock Day Podcast


Phoenix, November 5, 2018 (GLOBE NEWSWIRE) – Dennis Calvert, CEO of BioLargo, Inc. (OTCQB:BLGO), recently spoke with Stock Day Podcast’s Everett Jolly to update listeners on the company’s recent milestones.



Jolly started out the interview highlighting that BioLargo’s odor and VOC control products are set to do over $1 million in revenue in 2018.

“We launched the product about two years ago into the municipal waste handling industry”, Calvert explains to Uptick. “It took us about a year to get our foothold in the market and over the past six months, we signed national purchasing agreements with four of the top municipal waste handling companies in the country and have enjoyed 100% regional adoption with those accounts in Southern California, so the market is finally catching on that ours is a great product backed by great service. We are also servicing early adopters in the waste water treatment industry and new industries are just getting started as well. We have also transitioned from being a tech shop to a solutions provider, adding engineering, system design, installation, maintenance and service. We have only scratched the surface of the global opportunity for CupriDyne Clean.”

Jolly then shifted the interview to talk about Clyra Medical Technologies, Inc., the BioLargo subsidiary that uses innovative patent protected chemistry in advanced wound care. Calvert discussed the progress of its advanced wound care products under its subsidiary Clyra Medical Technologies, and its recent 510 (k) application with the FDA.

In a follow-up to the interview, Calvert expanded on their recent trip to Washington, DC to meet with the FDA about the company’s pending application, “In our meeting with FDA representatives last week, we were able to clarify the data requirements and the appropriate pathway to success for our application. The first series of questions asked of our team relates to labeling, shelf-life, and composition, and we think that request and the answers are straight forward. The more important request they made was that we conduct a short-term live animal study which requires a small period of work and money to accomplish. We believe the time frame to meet these requests is manageable within the next few months, and that the outcome will ultimately result in FDA clearance of the product.”


Jolly also asked Dennis about BioLargo Water’s AOS (Advanced Oxidation System), which is a technological breakthrough in water and wastewater treatment and has the potential to provide effective and cost-efficient elimination of pathogens and hard-to-treat organics from wastewater. Calvert said the product is nearing commercialization and is even currently part of several pre-commercial pilot projects in real world industrial settings. He also went on to explain the exciting independent 3rd-party validation of the high-value use of the AOS for managing micropollutants and other hard-to-treat contaminants for the wastewater industry.

“We have major projects that all focus on taking the system into the field to work with real clients to prove out its real economic value,” Calvert explained. “It’s the final piece of making that technology ready for market. We think it’s pretty exciting.”

To hear the entire interview with Dennis Calvert, click the Stock Day podcast link (https://upticknewswire.com/featured-interview-ceo-dennis-calvert-of-biolargo-inc-otcqb-blgo-10/).



About BioLargo, Inc.

BioLargo, Inc. is an innovative technology developer and environmental engineering company driven by a mission to "make life better" by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air, and advanced wound care. We develop and commercialize disruptive technologies by providing the capital, support, and expertise to expedite them from "cradle" to "maturity" (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. Our subsidiary Clyra Medical (www.clyramedical.com) features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

Contact Information:
Dennis Calvert President and CEO BioLargo, Inc. 949-643-9540 x2

Safe Harbor Act

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

About Uptick Newswire and the “Stock Day” Podcast

Founded in 2013, Uptick Newswire is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Uptick provides companies with customized solutions to their news distribution in both national and international media outlets. Uptick is the sole producer of its “Stock Day” Podcast, which is the number one radio show of its kind in America. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire, which recently launched its Video Interview Studio located in Phoenix, Arizona.

Investors Hangout is a proud sponsor of “Stock Day,” and Uptick Newswire encourages listeners to visit the company’s message board at https://investorshangout.com/

SOURCE:
Uptick Newswire

Wednesday, 31 October 2018

BioLargo Letter to Stockholders: Recent Milestones and Successes (Oct 31 2018)


The pace quickens with key breakthroughs and our commercial track becomes more well defined than ever before
October 31st, 2018

Dear Stockholder,

Today I want to bring you an update on the progress that each of our business units has made in the past few months, and share with you why we remain confident that our progress will translate to growth in the near- and long-term. Each of our businesses faces challenges in their road to commercial success, and it’s important to highlight when those challenges are overcome, because those moments underline the innovation, tenacity, and perseverance of the BioLargo team that drives this business forward. Of course, we encourage you to review our SEC filings for the most complete view of our business and outlook (link HERE), and remind you that our third quarter results will be filed by November 14, 2018.

Let’s dig in. We’ll examine our business units one-by-one and focus on the important progress that has been made in each one. I encourage you to reach out to me if you have any specific questions on anything you read here.

Odor-No-More

Odor-No-More is on track to exceed $1 million in revenue for 2018, and we should break this record soon. This is an important milestone! Looking back, in 2017 we were at just over a half million, and in 2016 just over a quarter million dollars in revenue. As you can imagine, we’re excited to pass this threshold, and we believe it bodes well for our future. What accounts for the improvement? Hard work and perseverance. And, it helps to be selling the number one performer in the marketplace. CupriDyne Clean has been a big hit in the waste handling industry, and orders from the US military for our products developed for the US Military keep coming in. Let’s review:

·         CupriDyne Clean - Industrial Odor and VOC Eliminator
o   4 national accounts
o   Focused on regional adoption (and succeeding - 100% of locations owned by industry leaders in LA and Orange County California) – we are rolling out the product location-by-location, region-by-region
o   Big potential in waste industry – current customers operate almost 2,000 locations nationwide that could use our product.
o   We’re not just selling product – we are now a full-service firm, designing and installing systems to deliver CupriDyne Clean and being asked to manage other improvements. This translates to greater customer retention.
o   Expanding to other industries (new customer manufactures steel) and opportunities expanding in wastewater treatment.
o   Money and infrastructure needed – with any growing business, we need the resources to hire more salespeople and open new offices

BioLargo Engineering, Science & Technologies (BLEST)

BioLargo Engineering, Science & Technologies (BLEST) is our team of veteran environmental engineers based in Oak Ridge, TN who began working for us one year ago. They are hard at work supporting our Canadian research team and Odor-No-More, and also doing work for outside clients in traditional engineering roles. Their next milestone is profitability – that is to say their revenue from outside clients exceeding expenses.

Clyra Medical Technologies

Our medical subsidiary, Clyra, was formed to develop advanced wound care products featuring our BioLargo technologies. Recently, we acquired a stem cell therapy technology for the treatment of chronic wounds (link to 8-K here). We believe this product has the potential to create enormous value for our company and our shareholders, and also to provide superior advanced wound care for patients all around the world. (See more details below.)

Our antimicrobial advanced wound care products have a bright future ahead of them, and the market potential for them is huge, especially given the synergy with our new stem cell technology. That being said, as with any medical product, there are significant hurdles that innovators in this space must overcome before reaching commercial success with Clyra wound care products. I’d like to take the time to address one of these hurdles – the regulatory process:

·         We submitted premarket notification to the FDA under Section 510(k) in late June of 2018 for an advanced wound care product. The FDA responded by identifying areas of concern and requesting additional information to address those concerns.   
·         Our management recently met in Washington DC with representatives from the FDA to clarify the concerns and additional information requested, and the optimal pathway forward for approval of our product.  
o   The meeting was successful in that the discussion enabled management to identify a clear pathway to the successful clearance of the application. 
o   The primary focus of request for information by the FDA has been narrowed to two areas, one of which will require us to conduct a live animal study.
o   Clyra is working diligently to confirm the appropriate test protocols, secure appropriate GLP laboratories, and negotiate the package of services by third party experts to perform this work. We believe the time frame to meet these requests is manageable within the next few months, and that the outcome will ultimately result in FDA clearance of the product.
o   While we remain confident that we will ultimately receive premarket clearance for this product, we can make no assurance or prediction as to success of these efforts and must wait patiently for the process with the FDA to conclude. Clyra has numerous medical device product designs that it intends to pursue in the future as resources permit.
·         We recently executed definitive agreements to acquire a break-through stem cell therapy technology (8-k link here), which is licensed from BioLargo to Clyra in exchange for long-term license equal to 3% of sales and an increase of BioLargo’s ownership of Clyra to approximately 60% Clyra shares on a pre-money basis. This final closing of the transaction is conditioned upon $1M of direct investment into Clyra from outside investors.

BioLargo Water

BioLargo Water’s Advanced Oxidation System (AOS) is a technological breakthrough in water and wastewater treatment and has the potential to provide effective and cost-efficient elimination of pathogens and hard-to-treat organics in countless water treatment markets and applications. Like all water treatment technologies, the AOS is complex, and with complexity comes technical barrier-to-entry that must be overcome. We have overcome innumerable challenges in the development of the AOS, and we’re proud to say this product is nearing commercialization and is even currently part of several pre-commercial pilot projects in real world industrial settings – a major milestone. Let’s review some of the highlights on the AOS’ progress:

·         BioLargo has received over 60 government and industry grants supporting research and development of the AOS
·         Commercial progress:
o   Currently involved in two pre-commercial pilots, and on-site work is slated to begin in the 4th quarter of 2018. These pilots, which are at a poultry producer and a microbrewery, represent a critical step toward commercialization, as they will provide crucial real-life technical and economic data required for the technology’s adoption by future customers.
o   We are preparing for two additional on-site pilots in the stormwater and industrial wastewater markets, plus one important validation project in the oil and gas industry.
·         The AOS was recently validated by an independent third-party expert that conducted a study of the AOS’s ability to eliminate specific micro-pollutants which was summarized for the company in a confidential written report. The results are currently being prepared for scientific publication and expanded patent coverage. We intend to disclose additional information about this confirmation breakthrough as it becomes available in the near future.
·         BioLargo Water and BioLargo Engineering are collaborating to prepare the AOS for commercialization, including materials engineering work to prepare the AOS for mass production, longer useful lifespan, ruggedization, and logistical challenges that it will face in commercial settings.

BioLargo Corporate

Behind the scenes, BioLargo’s corporate office is advancing the company’s varied business interests tirelessly. We’ve accomplished some important work recently:
·         The successful conversion of $6.4 million of debt to equity (link to Press Release)
·         The extension of existing short-term debt and the securing new bridge financing since September totaling $1,270,000- (See our 8-k reports on the topic here)
·         The company is working to meet its stated goal to uplist the company’s common stock to Nasdaq or equivalent national market (link to 8-k)
·         The first analyst coverage was initiated by The Edison Group and is a great tool to help the market understand our business (link to analyst report)

Closing Remarks

Given our recent commercial wins and scientific advances, this is the most exciting time in our company’s history. Yet, because everyone (including me) would love to have arrived at these breakthrough moments faster, it can also seem like the most challenging time. With limited capital resources, we have labored tirelessly to fully develop and prove out our innovations and the disruptive nature of our products.

We are poised for significant commercial success as resources and strategic relationships will continue to expand in our favor. The next step in our journey will depend on proper capital, having the right people, precise execution, and most importantly – patience.

Thank you for your continued support, and feel free to contact me at any time! 

Dennis P. Calvert
President and CEO
BioLargo, Inc.


About BioLargo, Inc.
BioLargo, Inc. is an innovative technology developer and environmental engineering company driven by a mission to "make life better" by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air, and advanced wound care. We develop and commercialize disruptive technologies by providing the capital, support, and expertise to expedite them from "cradle" to "maturity" (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. Our subsidiary Clyra Medical (www.clyramedical.com) features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.
Contact Information Dennis Calvert President and CEO BioLargo, Inc. 949-643-9540 x2


Safe Harbor Act

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.



widget